We recommend using a newer internet browser, such as Google Chrome or Microsoft Edge, to optimize your browsing experience.

Skip to main content

Reslizumab in Patients With Corticosteroid Dependent Asthma and Elevated Eosinophils

- Asthma | Elevated Blood Eosinophils | Oral Corticosteroid Dependence
- Completed

Study Title: An Efficacy and Safety Study of Reslizumab Subcutaneous in Patients With Oral Corticosteroid Dependent Asthma and Elevated Blood Eosinophils

Teva Identifier: C38072-AS-30027 | 2015-001580-39

ClinicalTrials.gov Identifier: NCT02501629

Study Status: Completed

Trial Condition(s): Asthma | Elevated Blood Eosinophils | Oral Corticosteroid Dependence

Interventions: Drug: Reslizumab | Drug: Placebo | Drug: Non-Oral Corticosteroid (non-OCS) Asthma Medication | Drug: Oral Corticosteroid (OCS)

Study Description: Please refer to ClinicalTrials.gov for a description of the trial

Click for participation criteria and map of study locations

Key Participation Requirements

Gender: Female, Male

Age Range: 12 Years and older

Trial Duration: September 29, 2015 - December 4, 2017

Phase: Phase 3

Study Type

Interventional